Nevro Corp. NVRO recently announced preliminary revenues for second-quarter 2021. The company expects to release detailed financial results for the period on Aug 4.As per the preliminary report, second-quarter 2021 revenues are estimated to be $102.3 million, up by 81% from the year-ago quarter. The Zacks Consensus Estimate of $102.9 million remains above the preliminary figure.The company, during its first-quarter 2021 earnings release in May, had guided second-quarter 2021 worldwide revenues in the band of $104-$106 million, reflecting growth of 84-88%.Nevro expects its second-quarter 2021 U.S. revenues to be approximately $85 million, reflecting an uptick of 67% from the prior-year period. International revenues are expected to be around $17.3 million, indicating an improvement of 222% on a reported basis (up 191% at constant exchange rate) compared with the year-ago period.Following this release on Jul 19, shares of the company were up 1% to close at $151.44 yesterday.2021 Financial OutlookOn the back of continued pandemic-led uncertainties, Nevro plans to update its guidance for full-year 2021 when it reports full second-quarter financial results.Nonetheless, the company, during its first-quarter 2021 earnings release, had narrowed its financial outlook for the full-year 2021. It expected full-year 2021 revenues in the band of $440-$450 million, narrower than the previous range of $430-$450 million. This reflects an improvement of 22-24%. The Zacks Consensus Estimate for full-year revenues is currently pegged at $444.1 million.The company’s expectation of mid-single-digit million revenue contribution in 2021 from Painful Diabetic Neuropathy treatment following its FDA approval of Senza System (which is specific to Nevro's 10 kHz stimulation) looks encouraging.A Brief Q2 AnalysisNevro has been observing a slower-than-expected recovery of procedural volumes in the overall pain market and specifically in the spinal cord stimulation market. This, in turn, has adversely impacted not only second-quarter revenues, but also resulted in lower trial procedures, which drove down revenues.Meanwhile, the company’s preliminary projection of a robust improvement in revenues compared with the sequentially last-reported quarter, lifts our confidence.Price PerformanceShares of the company have gained 13.1% in the past year compared with the industry’s 11.2% growth and the S&P 500's 31.6% rise.Image Source: Zacks Investment ResearchZacks Rank & Key PicksCurrently, Nevro carries a Zacks Rank #3 (Hold).Some better-ranked stocks from the broader medical space are Henry Schein, Inc. HSIC, AMN Healthcare Services Inc AMN and Align Technology, Inc. ALGN.Henry Schein’s long-term earnings growth rate is estimated at 11.2%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.AMN Healthcare’s long-term earnings growth rate is estimated at 6.5%. It currently carries a Zacks Rank #2.Align Technology’s long-term earnings growth rate is estimated at 23.2%. It currently carries a Zacks Rank #2. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report Nevro Corp. (NVRO): Free Stock Analysis Report To read this article on Zacks.com click here.